Suppr超能文献

综述:羟氯喹啉和氯喹啉用于治疗严重急性呼吸综合征冠状病毒2(COVID-19)

Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19).

作者信息

Pastick Katelyn A, Okafor Elizabeth C, Wang Fan, Lofgren Sarah M, Skipper Caleb P, Nicol Melanie R, Pullen Matthew F, Rajasingham Radha, McDonald Emily G, Lee Todd C, Schwartz Ilan S, Kelly Lauren E, Lother Sylvain A, Mitjà Oriol, Letang Emili, Abassi Mahsa, Boulware David R

机构信息

Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota.

出版信息

Open Forum Infect Dis. 2020 Apr 15;7(4):ofaa130. doi: 10.1093/ofid/ofaa130. eCollection 2020 Apr.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是一种迅速出现的病毒感染,可导致2019冠状病毒病(COVID-19)。在几项小型临床试验、非对照病例系列研究以及公众人物的支持下,羟氯喹和氯喹作为对抗COVID-19的潜在治疗药物受到了前所未有的关注。虽然科学数据越来越多,但也有人担心其危害,尤其是QTc延长和心律失常。在此,我们进行了一项快速叙述性综述,并讨论了现有研究和临床研究的优势与局限性。我们呼吁在将羟氯喹和氯喹广泛纳入国家和国际治疗指南之前,获得更多随机对照试验的证据。

相似文献

1
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19).
Open Forum Infect Dis. 2020 Apr 15;7(4):ofaa130. doi: 10.1093/ofid/ofaa130. eCollection 2020 Apr.
2
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
3
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
Ann Intern Med. 2020 Aug 18;173(4):287-296. doi: 10.7326/M20-2496. Epub 2020 May 27.
6
Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.
Clin Toxicol (Phila). 2021 Jan;59(1):12-23. doi: 10.1080/15563650.2020.1817479. Epub 2020 Sep 22.
8
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.
10
Chloroquine and its derivatives in the management of COVID-19: A scoping review.
Biomedica. 2020 Oct 30;40(Supl. 2):80-95. doi: 10.7705/biomedica.5478.

引用本文的文献

4
Evaluation of weak genotoxicity of hydroxychloroquine in human TK6 cells.
Toxicol Lett. 2024 Mar;393:84-95. doi: 10.1016/j.toxlet.2024.01.012. Epub 2024 Feb 2.
5
Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection.
Signal Transduct Target Ther. 2023 Jun 7;8(1):237. doi: 10.1038/s41392-023-01510-8.
9
Free radical induced degradation and computational studies of hydroxychloroquine in aqueous solution.
Radiat Phys Chem Oxf Engl 1993. 2023 May;206:110785. doi: 10.1016/j.radphyschem.2023.110785. Epub 2023 Jan 14.
10
A comprehensive perspective of traditional Arabic or Islamic medicinal plants as an adjuvant therapy against COVID-19.
Saudi J Biol Sci. 2023 Mar;30(3):103561. doi: 10.1016/j.sjbs.2023.103561. Epub 2023 Jan 13.

本文引用的文献

1
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
3
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
Int J Antimicrob Agents. 2020 May;55(5):105960. doi: 10.1016/j.ijantimicag.2020.105960. Epub 2020 Apr 3.
7
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
8
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
9
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
10
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验